ADMA Biologics/$ADMA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ADMA Biologics
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
Ticker
$ADMA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
685
ISIN
US0008991046
Website
ADMA Biologics Metrics
BasicAdvanced
$4.2B
21.05
$0.84
0.57
-
Price and volume
Market cap
$4.2B
Beta
0.57
52-week high
$25.67
52-week low
$10.21
Average daily volume
3M
Financial strength
Current ratio
6.576
Quick ratio
3.197
Long term debt to equity
21.645
Total debt to equity
21.963
Interest coverage (TTM)
12.53%
Profitability
EBITDA (TTM)
159.943
Gross margin (TTM)
52.58%
Net profit margin (TTM)
45.01%
Operating margin (TTM)
33.10%
Effective tax rate (TTM)
-46.89%
Revenue per employee (TTM)
$670,000
Management effectiveness
Return on assets (TTM)
22.06%
Return on equity (TTM)
78.45%
Valuation
Price to earnings (TTM)
21.046
Price to revenue (TTM)
9.01
Price to book
11.24
Price to tangible book (TTM)
11.36
Price to free cash flow (TTM)
45.846
Free cash flow yield (TTM)
2.18%
Free cash flow per share (TTM)
38.37%
Growth
Revenue change (TTM)
62.22%
Earnings per share change (TTM)
-5,277.07%
3-year revenue growth (CAGR)
69.70%
10-year revenue growth (CAGR)
54.68%
3-year earnings per share growth (CAGR)
19.45%
10-year earnings per share growth (CAGR)
-5.92%
What the Analysts think about ADMA Biologics
Analyst ratings (Buy, Hold, Sell) for ADMA Biologics stock.
Bulls say / Bears say
ADMA Biologics reported a 65% year-over-year increase in total revenue for FY 2024, reaching $426.5 million, driven primarily by increased sales of ASCENIV and BIVIGAM. (admabiologics.com)
The company achieved its first GAAP net income of $197.7 million in 2024, a significant turnaround from a net loss of $28.2 million in 2023, indicating strong financial health. (admabiologics.com)
ADMA secured long-term high-titer plasma supply contracts expected to support ASCENIV revenue growth through the late 2030s, ensuring a stable supply chain for its key product. (admabiologics.com)
Two customers accounted for approximately 72% of ADMA's consolidated revenues in 2024, indicating a high customer concentration risk. (panabee.com)
The company's reliance on non-GAAP financial measures may obscure true financial performance, potentially leading to misunderstandings among investors regarding actual profitability. (nasdaq.com)
Ongoing concerns about product withdrawals could impact future revenue stability and customer confidence in ADMA's offerings. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
ADMA Biologics Financial Performance
Revenues and expenses
ADMA Biologics Earnings Performance
Company profitability
ADMA Biologics News
AllArticlesVideos
ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update
GlobeNewsWire·2 months ago
3 Mid-Cap Medical Stocks Outperforming the Market
MarketBeat·2 months ago
ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ADMA Biologics stock?
ADMA Biologics (ADMA) has a market cap of $4.2B as of July 18, 2025.
What is the P/E ratio for ADMA Biologics stock?
The price to earnings (P/E) ratio for ADMA Biologics (ADMA) stock is 21.05 as of July 18, 2025.
Does ADMA Biologics stock pay dividends?
No, ADMA Biologics (ADMA) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next ADMA Biologics dividend payment date?
ADMA Biologics (ADMA) stock does not pay dividends to its shareholders.
What is the beta indicator for ADMA Biologics?
ADMA Biologics (ADMA) has a beta rating of 0.57. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.